(For consistency, the abbreviations used throughout this announcement shall have the same meaning as defined in the announcement dated 4 December 2020, 8 December 2020, 6 January 2021, 7 January 2021 and 9 February 2021 in relation to the Proposed Collaboration, where applicable, unless stated otherwise or defined herein.)

Following the Definitive Agreement signed between YTB Healthcare Sdn Bhd (“YTBH”), a subsidiary of the Company, and SZKT on 9 Feb 2021, the Board wishes to announce that YTBH had on 15 March 2021 submitted its Phase III Clinical Trial Application to Medical Review & Ethics Committee ("MREC") for study approval and National Pharmaceutical Regulatory Agency ("NPRA") of Ministry of Health ("MOH") for Clinical Trial Import Licence (“CTIL”) screening submission.

Barring any unforeseen circumstances and subject to the above approvals, YTBH expects to commence the Phase III Clinical Trial in Malaysia by second quarter of 2021.

Please find attached a media release dated 15 March 2021 in relation to the abovementioned matter.

This announcement is dated 15 March 2021.